|本期目录/Table of Contents|

[1]赵青春,韦 森,张洪兵,等.分析第6版和第7版TNM分期在肺腺癌患者中的差异[J].天津医科大学学报,2015,21(05):432-436.
点击复制

分析第6版和第7版TNM分期在肺腺癌患者中的差异(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
21卷
期数:
2015年05期
页码:
432-436
栏目:
临床医学
出版日期:
2015-09-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2015)05-0432-05
作者:
赵青春; 韦 森; 张洪兵; 任 典; 陈 军
(天津医科大学总医院肺部肿瘤外科,天津 300052)
Author(s):
-
关键词:
肺腺癌; TNM分期; 跨叶型肺癌; 靶向治疗; 基因突变; 预后
Keywords:
-
分类号:
R734.2
DOI:
-
文献标志码:
A
摘要:
目的:分析国际肺癌研究协会第6版和第7版TNM分期在肺腺癌患者中的差异。方法：对302例术后确诊为肺腺癌的患者按照第6版和第7版TNM分期标准进行重新分期，对比两种分期下患者的分期组成结构及预后情况。结果：入组患者中共有71(23.5%)例存在分期变动，其中36(11.9%)例分期升级，35(11.6%)例分期降级。生存分析结果显示第7版分期与第6版分期在肺腺癌患者中无显著差异，且相邻组别之间术后生存时间未见明显差异。结论：肺腺癌复杂的病理组织亚型和高基因突变率以及跨叶型肺癌特殊的T分期均会影响患者的预后。结合临床分期、病理类型以及基因型等多因素共同评估患者预后将成为诊治肺腺癌新的发展趋势。
Abstract:
-

参考文献/References:

[1]Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J].CA Cancer J Clin,2009,59(4):225
[2]Groome P A, Bolejack V, Crowley J J, et al. The IASLC lung Cancer staging project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours[J].J Thorac Oncol,2007,2(8):694
[3]Kameyama K, Takahashi M, Ohata K, et al. Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution[J].J Thorac Cardiovasc Surg,2009,137(5):1180
[4]Fukui T, Mori S, Hatooka S, et al. Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers[J].J Thorac Cardiovasc Surg,2008,136(5):1343
[5]Ruffini E, Filosso P L, Bruna M C, et al. Recommended changes for T and N descriptors proposed by the International Association for the Study of Lung Cancer-Lung Cancer Staging Project:a validation study from a single-centre experience[J].Eur J Cardiothorac Surg,2009,36(6):1037
[6]Suzuki M, Yoshida S, Tamura H, et al. Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers[J].Eur J Cardiothorac Surg, 2009, 36(6):1031
[7]Yoshida Y, Murayama T, Sato Y, et al. Validation of 7th TNM staging system for lung Cancer,based on surgical outcomes[J].Asian Cardiovasc Thorac Ann,2013,21(6):693
[8]Travis W D, Brambilla E, Noguchi M, et al. International association for the study of lung Cancer/American thoracic society/European respiratory society:international multidisciplinary classification of lung adenocarcinoma:executive summary[J].Proc Am Thorac Soc, 2011, 8(5): 381
[9]Li G Q, Luo X D, He J Y, et al. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue[J].Clin Chem Lab Med,2011,49(2):191
[10]Inamura K, Ninomiya H, Ishikawa Y A. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?[J].Arch Pathol Lab Med,2010,134(1):66
[11]Pao W, Girard N.New driver mutations in non-small-cell lung Cancer[J].Lancet Oncol,2011,12(2):175
[12]Li C, Sun Y H, Fang Z Y, et al. Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma[J].J Thorac Oncol,2011,6(6):1016
[13]Liam C K, Wahid M, Rajadurai P, et al. Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients[J].J Thorac Oncol,2013,8(6):766
[14]Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients[J].J Thorac Oncol,2013,8(1):52
[15]Bauml J, Mick R, Zhang Y, et al. Frequency of EGFR and KRAS mutations in patients with non small cell lung Cancer by racial background: Do disparities exist?[J].Lung Cancer,2013,81(3):347
[16]Boch C, Kollmeier J, Roth A, et al. The frequency of EGFR and KRAS mutations in non-small cell lung Cancer(NSCLC):routine screening data for central Europe from a cohort study[J].BMJ Open,2013,3(4)
[17]Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung Cancer with mutated EGFR[J].N Engl J Med,2010,362(25):2380
[18]Miura H, Taira O, Uchida O, et al. Invasion beyond interlobar pleura in non-small cell lung Cancer[J].Chest,1998,114(5):1301
[19]Okada M, Tsubota N, Yoshimura M, et al. How should interlobar pleural invasion be classified? Prognosis of resected T3 non-small cell lung Cancer[J].Ann Thorac Surg,1999,68(6):2049
[20]Demir A, Gunluogtu M Z, Sansar D, et al. Staging and resection of lung Cancer with minimal invasion of the adjacent lobe[J].Eur J Cardiothorac Surg,2007,32(6):855
[21]Yang H X, Hou X, Lin P, et al. Peripheral direct adjacent lobe invasion non-small cell lung Cancer has a similar survival to that of parietal pleural invasion T3 disease[J].J Thorac Oncol,2009,4(11):1342
[22]Haam S J, Park I K, Paik H C, et al. T-stage of non-small cell lung Cancer directly invading an adjacent lobe[J].Eur J Cardiothorac Surg,2012,42(5):807
[23]Nonaka M, Kataoka D, Yamamoto S, et al. Outcome following surgery for primary lung Cancer with interlobar pleural invasion[J].Surg Today,2005,35(1):22
[24]贾克刚，丛伟，薛洋，等. 非小细胞肺癌合并孤立脑转移灶的手术疗效观察[J].华西医学,2012, (11):1634

相似文献/References:

[1]林高阳,徐 克.氯化锂调控人肺腺癌A549细胞增殖侵袭转移的体外研究[J].天津医科大学学报,2015,21(01):9.
　LIN Gao-yang,XU Ke.Investigation of the effect of lithium chloride on proliferation and metastasis potential of human lung adenocarcinoma A549 cells in vitro[J].Journal of Tianjin Medical University,2015,21(05):9.
[2]董傲然,张家丽,任秀宝,等.促胃泌素释放肽前体对小细胞肺癌的诊断价值[J].天津医科大学学报,2019,25(03):234.
　DONG Ao-ran,ZHANG Jia-li,REN Xiu-bao,et al.Diagnosis value of pro-gastrin-releasing peptide precursor for small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(05):234.
[3]高周勇,张文成,王广舜.基于TCGA数据库分析GTSE1基因在肺腺癌中的表达及意义[J].天津医科大学学报,2021,27(03):274.
　GAO Zhou-yong,ZHANG Wen-cheng,WANG Guang-shun.Expression and significance of GTSE1 gene in lung adenocarcinoma based on TCGA database[J].Journal of Tianjin Medical University,2021,27(05):274.
[4]李世雄,耿华,徐美林.肿瘤微环境中免疫与基质细胞相关基因在肺腺癌中的预后价值[J].天津医科大学学报,2022,28(01):47.
　LI Shi-xiong,GENG Hua,XU Mei-lin.Prognostic value of immune and stromal cell-related genes in tumor microenvironment in lung adenocarcinoma[J].Journal of Tianjin Medical University,2022,28(05):47.
[5]骆源,徐启飞,吕泽政,等.三维ResNet 网络预测肺腺癌结节亚型的效能及其 稳定性[J].天津医科大学学报,2022,28(03):295.
　LUO Yuan,XU Qi-fei,LYU Ze-zheng,et al.Efficacy and stability of 3D ResNet for predicting nodule subtypes in lung adenocarcinoma[J].Journal of Tianjin Medical University,2022,28(05):295.
[6]马梦楚,任媛媛,刘欣.肺腺癌细胞中PRDM5抑癌作用的分子机制初探[J].天津医科大学学报,2022,28(04):360.
　MA Meng-chu,REN Yuan-yuan,LIU Xin.Preliminary study on the molecular mechanism of PRDM5 suppression in lung adenocarcinoma[J].Journal of Tianjin Medical University,2022,28(05):360.

备注/Memo

备注/Memo:

作者简介? 赵青春（1988-），男，硕士在读，研究方向：胸心外科学；通信作者：陈军，E-mail：huntercj2004@yahoo.com。

更新日期/Last Update: 2015-09-22